Vaccine and immunotherapeutic interventions

Current Opinion in HIV and AIDS

Volumn 8, Issue 3, 2013, Pages 236-242

  Pantaleo, Giuseppe ^a   Lévy, Yves ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b FACULTÉ DE MÉDECINE   (France)

Author keywords

HIV latent reservoir; immune intervention; immune response; T cell; therapeutic vaccination

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; DNA VACCINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; LIPOPEPTIDE; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1;

ADAPTIVE IMMUNITY; ANTIGEN EXPRESSION; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC INFLAMMATION; DENDRITIC CELL; HEREDITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; MEMORY CELL; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RESERVOIR; REVIEW; T LYMPHOCYTE; TRANSCRIPTION INITIATION; TREATMENT FAILURE; VACCINATION; VIREMIA; VIRUS REPLICATION;

AIDS VACCINES; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOTHERAPY; T-LYMPHOCYTES;

EID: 84876414249     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32835fd5cd     Document Type: Review

References (56)

1. Rong L, Perelson AS. Modeling HIV persistence, the latent reservoir, and viral blips. J Theoret Biol 2009; 260:308-331.
2. Deeks SG, Autran B, Berkhout B, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012; 12:607-614.
3. Hakre S, Chavez L, Shirakawa K, Verdin E. Epigenetic regulation of HIV latency. Curr Opin HIV AIDS 2011; 6:19-24.
4. Chan JK, Greene WC. NF-kappaB/Rel: agonist and antagonist roles in HIV-1 latency. Curr Opin HIV AIDS 2011; 6:12-18.
5. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36:491-501.
6. Kalams SA, Goulder PJ, Shea AK, et al. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol 1999; 73:6721-6728.
7. Vanham G, Van Gulck E. Can immunotherapy be useful as a 'functional cure' for infection with human immunodeficiency virus-1? Retrovirology 2012; 9:72.
8. Reuter MA, Pombo C, Betts MR. Cytokine production and dysregulation in HIV pathogenesis: lessons for development of therapeutics and vaccines. Cytokine Growth Factor Rev 2012; 23:181-191.
9. Perreau M, Savoye AL, De Crignis E, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2013; 210:143-156.
10. van Praag RM, Prins JM, Roos MT, et al. OKT3 and IL-2 treatment for purging of the HIV latent reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol 2001; 21:218-226.
11. Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Elite controllers as a model of functional cure. Curr Opin HIV AIDS 2011; 6:181-187.
12. Bailey JR, O'Connell K, Yang HC, et al. Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. J Virol 2008; 82:7395-7410.
13. Buckheit RW 3rd, Allen TG, Alme A, et al. Host factors dictate control of viral replication in two HIV-1 controller/chronic progressor transmission pairs. Nat Commun 2012; 3:716.
14. Levy Y, Ellefsen K, Stöehr W, et al. Optimal priming of poxvirus vector-based HIV vaccine regimens requires 3 DNA injections: results of randomized multicentre EV03/ANRS Vac20 Phase I/II Trial. Program & Abstracts, 17th Conference of Retrovirus and Opportunistic Infections (CROI), 16-19 February 2010, Moscone Center West, San Francisco, CA, USA.
15. Harari A, Rozot V, Cavassini M, et al. NYVAC immunization induces poly-functional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients. Eur J Immunol 2012; 42:3038-3048.
16. Gudmundsdotter L, Wahren B, Haller BK, et al. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial. Vaccine 2011; 29:5558-5566.
17. Vardas E, Stanescu I, Leinonen M, et al. Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU((R))-Multi-HIVB, in untreated HIV-1 infected subjects. Vaccine 2012; 30:4046-4054.
18. Ilves I, Kivi S, Ustav M. Long-term episomal maintenance of bovine papillo-mavirus type 1 plasmids is determined by attachment to host chromosomes, which Is mediated by the viral E2 protein and its binding sites. J Virol 1999; 73:4404-4412.
19. Schooley RT, Spritzler J, Wang H, et al. AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. J Infect Dis 2010; 202:705-716.
20. Li JZ, Brumme ZL, Brumme CJ, et al. Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J Infect Dis 2011; 203:976-983.
21. Garcia F, Climent N, Assoumou L, et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis 2011; 203:473-478.
22. Routy JP, Nicolette C. Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection. Immunotherapy 2010; 2:467-476.
23. Allard SD, De Keersmaecker B, deGoede AL, et al. Aphase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption. Clin Immunol 2012; 142:252-268.
24. Van Gulck E, Vlieghe E, Vekemans M, et al. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS 2012; 26:F1-12.
25. Lisziewicz J, Bakare N, Calarota SA, et al. Single Derma Vir immunization: dose-dependent expansion of precursor/memory T cells against all HIV antigens in HIV-1 infected individuals. PLoS One 2012; 7:e35416.
26. Climent N, Guerra S, Garcia F, et al. Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals. PLoS One 2011; 6:e19644.
27. Garcia F, Climent N, Guardo AC, et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Trans Med 2013; 5:166ra2.
28. Cobb A, Roberts LK, Palucka AK, et al. Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine. J Immunol Meth 2011; 365:27-37.
29. Levy Y, Thiébaut R, Montes M, et al. Vaccine of HIV-1 Patients with dentritic cells loaded with HIV-1 lipopeptides elicits broad T cell immunity associated to a reduced peak of HIV-1 viral load following HAART interruption. ANRS Vaccine Network; 19th Conference on Retroviruses and Opportunistic infections (CROI), Washington Convention Center, Seattle, WA. 5-8 March 2012.
30. Trumpfheller C, Longhi MP, Caskey M, et al. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med 2012; 271:183-192.
31. Flynn BJ, Kastenmuller K, Wille-Reece U, et al. Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci USA 2011; 108:7131-7136.
32. Ueno H, Klechevsky E, Schmitt N, et al. Targeting human dendritic cell subsets for improved vaccines. Semin Immunol 2011; 23:21-27.
33. Le-Grand R, Zurawski S, Dereuddre-Bosquet N, et al. Targeting HIV Gag p24 to nonhuman primate dendritic cells via DCIR and langerin evoke potent and long-lasting antibody responses. AIDS Res Hum Retroviruses 2011; 27.
34. Calarota SA, Weiner DB. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev 2004; 199:84-99.
35. Kalams SA, Parker S, Jin X, et al. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults. PLoS One 2012; 7:e29231.
36. Levy Y, Lacabaratz C, Weiss L, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119:997-1007.
37. Levy Y, Sereti I, Tambussi G, et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012; 55:291-300.
38. Sereti I, Dunham RM, Spritzler J, et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113:6304-6314.
39. Bosque A, Famiglietti M, Weyrich AS, et al. Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells. PLoS Path 2011; 7:e1002288.
40. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350-354.
41. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12:1198-1202.
42. Porichis F, Kwon DS, Zupkosky J, et al. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood 2011; 118:965-974.
43. Dyavar Shetty R, Velu V, Titanji K, et al. PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J Clin Invest 2012; 122:1712-1716.
44. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-2465.
45. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-2454.
46. Richert L, Hue S, Hocini H, et al. Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers. AIDS (in press).
47. Richert L, Montes M, Surenaud M, et al. A score for data integration of immunological data: application to HIV therapeutic vaccine development. Washington: ANRS Vaccine Network/Vaccine Research Institute; 2012.
48. Wick WD, Yang OO, Corey L, Self SG. How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill? J Virol 2005; 79:13579-13586.
49. Guedj J, Thiebaut R, Commenges D. Maximum likelihood estimation in dynamical models of HIV. Biometrics 2007; 63:1198-1206.
50. Thiebaut R, Sereti I, Drylewicz J, et al. Understanding and predicting the effect of interleukin-7 in HIV-1 infected patients: a mathematical analysis of a phase I/IIa study. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 12-15 September 2010; Boston, MA, USA.
51. Perreau M, Welles HC, Harari A, et al. DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa. J Virol 2011; 85:9854-9862.
52. Cimbro R, Vassena L, Arthos J, et al. IL-7 induces expression and activation of integrin alpha4beta7 promoting naive T-cell homing to the intestinal mucosa. Blood 2012; 120:2610-2619.
53. Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Meth Mol Biol 2005; 304:3-15.
54. Lévy Y. Preparation for antiretroviral interruption by boosting the immune system. Curr Opin HIV AIDS 2008; 3:118-123.
55. + cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197:1145-1155.
56. Routy JP, Boulassel MR, Nicolette CA, Jacobson JM. Assessing risk of a short-term antiretroviral therapy discontinuation as a read-out of viral control in immune-based therapy. J Med Virol 2012; 84:885-889.